Gradientech
Fighting antibiotic resistance
- CEO: Sara Thorslund
- First investment year: 2011
- Fund: Eastern Mid Sweden
- Business sector: Life Science

Gradientech provides precision assays and software solutions for high-quality analysis of cell behavior in response to gradients of signalling molecules. Driven by the increased global prevalence of antibiotic resistance, Gradientech is developing its microfluidic platform QuickMIC - the most rapid IVD system for antibiotic susceptibility testing of sepsis patients.